RT Journal Article
SR Electronic
T1 SARS-CoV-2 seroprevalence in Chattogram, Bangladesh before the Delta surge, March-June 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.16.21260611
DO 10.1101/2021.07.16.21260611
A1 Bhuiyan, Taufiqur Rahman
A1 Dent Hulse, Juan
A1 Hegde, Sonia T.
A1 Akhtar, Marjahan
A1 Islam, Md. Taufiqul
A1 Hasan Khan, Zahid
A1 Khan, Ishtiakul Islam
A1 Ahmed, Shakeel
A1 Rashid, Md Mamunur
A1 Rashid, Rumana
A1 Gurley, Emily S.
A1 Shirin, Tahmina
A1 Khan, Ashraful Islam
A1 Azman, Andrew S.
A1 Qadri, Firdausi
YR 2021
UL http://medrxiv.org/content/early/2021/09/30/2021.07.16.21260611.abstract
AB In a representative serosurvey conducted March–June 2021, 64.1% (95%CrI 60.0– 68.1%) of Sitakunda subdistrict (Bangladesh) had anti-SARS-CoV-2 IgG antibodies after adjusting for age, sex, household clustering and test performance. Before the surge of Delta, most of the population had been infected despite low incidence of virologically-confirmed COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Bill and Melinda Gates Foundation [grant number INV-021879]. The authors would like to thank the Ministry of Health and Family Welfare (MOHFW) of Bangladesh. The authors would also like to express their sincere thanks to the staff members of icddr,b for their dedicated work in the field and laboratory during this pandemic situation. icddr,b is thankful and supported by the Governments of Bangladesh, Canada, Sweden, and the UK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was given by ethical review committees from both Johns Hopkins University and International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting these estimates are publicly available in the sitakunda-sarscov2-round1 repository in Github. https://github.com/HopkinsIDD/sitakunda-sarscov2-round1